English
Italiano
Log In(current)
Repository logoRepository logo
Who We Are✱Collections✱Initiatives✱Contacts
  1. Home
  2. PUBBLICAZIONE/PUBLICATION
  3. Journal Article
  4. Gender disparities in coronavirus disease 2019 clinical trial leadership

Gender disparities in coronavirus disease 2019 clinical trial leadership

Publication type
journal article
Publication date
2021
Author(s)
Cevik, Muge
Haque, Syed Arefinul
Manne-Goehler, Jennifer
Kuppalli, Krutika
Sax, Paul E.
more
Language
English
Keywords

COVID-19

Female

Humans

Leadership

Male

Sexism

Women

Gender

Breast Neoplasms

Research Personnel

Clinical Trials as To...

Coronavirus disease 2...

Pandemic

Coronavirus

Diabetes Mellitus, Ty...

Novel coronavirus

Severe acute respirat...

Sex Ratio

Discipline(s)

Clinical Medicine

Covid-19

Geographical area

Europe

Abstract
OBJECTIVES: To compare the gender distribution of clinical trial leadership in coronavirus disease 2019 (COVID-19) clinical trials. METHODS: We searched https://clinicaltrials.gov/ and retrieved all clinical trials on COVID-19 from 1 January 2020 to 26 June 2020. As a comparator group, we have chosen two fields that are not related to emerging infections and infectious diseases: and considered not directly affected by the pandemic: breast cancer and type 2 diabetes mellitus (T2DM) and included studies within the aforementioned study period as well as those registered in the preceding year (pre-study period: 1 January 2019 to 31 December 2019). Gender of the investigator was predicted using the genderize.io application programming interface. The repository of the data sets used to collect and analyse the data are available at https://osf.io/k2r57/. RESULTS: Only 27.8% (430/1548) of principal investigators among COVID-19-related studies were women, which is significantly different compared with 54.9% (156/284) and 42.1% (56/133) for breast cancer (p < 0.005) and T2DM (p < 0.005) trials over the same period, respectively. During the pre-study period, the proportion of principal investigators who were predicted to be women were 49.7% (245/493) and 44.4% (148/333) for breast cancer and T2DM trials, respectively, and the difference was not statistically significant when compared with results from the study period (p > 0.05). CONCLUSION: We demonstrate that less than one-third of COVID-19-related clinical trials are led by women, half the proportion observed in non-COVID-19 trials over the same period, which remained similar to the pre-study period. These gender disparities during the pandemic may not only indicate a lack of female leadership in international clinical trials and involvement in new projects but also reveal imbalances in women's access to research activities and funding during health emergencies.
Journal
Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN
1469-0691
DOI
10.1016/j.cmi.2020.12.025
Volume
27
Issue
7
Pagination
1007-1010
https://libkey.io/libraries/2561/articles/430541583/full-text-file?utm_source=api_2667&allow_speedbump=true
Repository logo
Sistema Bibliotecariodi Ateneo SBA
gendermore@unimore.it
www.sba.unimore.it

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify